PerpEquities
Gate.ioReference market
Closed- Regular hours
- 09:30 AM – 04:00 PM
- Next holiday
- Oct 1, 2026 · National Day
Equity · Healthcare
Sino Biopharmaceutical Limited (SINOBIOPHARM) perpetual futures
SINOBIOPHARM perpetual futures on 1 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade SINOBIOPHARMUSDT.
Sino Biopharmaceutical Limited tracked across crypto venues with normalized contract specifications.
$0.7152-1.8%
Price chart
–
Use the left and right arrow keys to inspect points on the chart.
Collecting venue price data...
venue perp mark · Gate.io (SBP/USDT)
Auto: highest-volume live perp venueOpen in TradingView
Trading data
Perpetual market activity
1/1 live markets
Trading data
Perpetual market activity
Venues
1
Live markets
1/1
24h volume
$2.8K
Open interest
$24.2K
Best liquidity
-
Tightest spread
+89.3 bps
Gate.io
Highest volume
$2.8K
Gate.io
Settlement mix
USDT · 1/1
Perp/spot vol.
-
OI / float
-
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100k
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100kNo sufficient depth · 0 of 1 venues absorb $10k
No fresh book data: Gate.io
Taker execution estimate incl. approx. fees - maker fills are not guaranteed.
Best venues for this underlying
Best liquidity
-No live data-
Tightest spread
SINOBIOPHARMHighest volume
SINOBIOPHARMFunding history
Stored venue snapshots by market
Funding history
Stored venue snapshots by marketCompany data
Company fundamentals
Updated 1h ago
Company data
Company fundamentals
Market cap
$12.7B
Updated 1h ago
Revenue
$5B
Trailing 12 months
Revenue growth
+14%
Next fiscal year
Profit margin
+7.1%
P/E
36.0
Peer P/E 1.6
Free cash flow
$768.1M
Trailing 12 months
More metrics
Net income
$355.4M
Trailing 12 months
P/S
2.5
Peer P/E
1.6
Similar listed perps
Revenue estimate
$5.4B
Next fiscal year
Earnings
2027-04-01
Revenue est. $2.5B · Updated 1h ago
Dividend
$0.07
2026-09-01
Fundamental detail
Annual + quarterlyLatest revenue$4.7B
Net margin+7.4%
Free cash flow$1.1B
Net debt$579.6M
PeriodRevenueGrowthNet incomeFCF
2020$3.5B-2%$412.2M$515.6M
2021$4B+14%$2.2B$516.5M
2022$3.9B-3%$378.4M$678.2M
2023$3.9B+1%$346.9M$648.9M
2024$4.3B+10%$520.6M$776.6M
2025$4.7B+10%$348.6M$1.1B
PeriodGross marginOperating marginNet marginROEROA
2020+78.1%+17.7%+11.7%+16.5%+5.9%
2021+80.1%+19.2%+54.4%+48.2%+24.1%
2022+82.8%+21.5%+9.8%+8.6%+4.0%
2023+81.0%+21.6%+8.9%+7.7%+3.7%
2024+81.5%+21.3%+12.1%+11.0%+5.4%
2025+82.1%+21.8%+7.4%+7.6%+3.1%
PeriodCashDebtNet debtCurrent ratio
2020$1.6B$2.1B$533.4M2.08
2021$1.4B$1.8B$374.6M1.53
2022$1.3B$2.1B$792.4M1.29
2023$1.4B$1.9B$465.3M1.05
2024$1.4B$1.5B$31.9M1.26
2025$1.8B$2.4B$579.6M1.37
PeriodMarket capEnterprise valueP/SP/E
2020$17.8B$18.3B5.042.3
2021$12.4B$12.8B3.15.7
2022$11.2B$12B2.936.7
2023$8.4B$8.8B2.130.4
2024$7.8B$7.8B1.830.2
2025$14.9B$15.5B3.142.7
PeriodRevenueGrowthNet incomeFCF
Q3 2024$966.3M-$35.9M$0
Q4 2024$966.3M-$35.9M$0
Q1 2025$1.3B+11%$252M$214.9M
Q2 2025$1.3B+11%$252M$214.9M
Q3 2025$1.1B+10%-$77.7M$384M
Q4 2025$1.1B+10%-$77.7M$384M
Q1 2026$1.4B+11%$255.4M$0
Q2 2026$1.4B+11%$255.4M$0
PeriodGross marginOperating marginNet marginROEROA
Q3 2024+80.8%+20.6%+3.7%+0.8%+0.4%
Q4 2024+80.8%+20.6%+3.7%+0.8%+0.4%
Q1 2025+82.5%+21.4%+19.3%+5.1%+2.3%
Q2 2025+82.5%+21.4%+19.3%+5.1%+2.3%
Q3 2025+81.6%+22.4%-7.3%-1.7%-0.7%
Q4 2025+81.6%+22.4%-7.3%-1.7%-0.7%
Q1 2026+83.0%+35.2%+17.7%+5.3%+2.1%
Q2 2026+83.0%+35.2%+17.7%+5.3%+2.1%
PeriodCashDebtNet debtCurrent ratio
Q3 2024$1.4B$1.5B$31.9M1.26
Q4 2024$1.4B$1.5B$31.9M1.26
Q1 2025$2.9B$1.8B-$1.2B1.36
Q2 2025$1.7B$1.8B$126.8M1.36
Q3 2025$1.8B$2.4B$578.5M1.37
Q4 2025$1.1B$2.4B$1.3B1.37
Q1 2026$2.2B$2.6B$340.5M1.63
Q2 2026$2.2B$2.6B$340.5M1.63
PeriodMarket capEnterprise valueP/SP/E
Q3 2024$8.6B$8.7B8.959.3
Q4 2024$7.8B$7.8B8.053.6
Q1 2025$9.4B$8.2B7.29.3
Q2 2025$12.9B$13B9.812.7
Q3 2025$19.9B$20.5B18.8-64.2
Q4 2025$14.9B$16.2B14.0-47.9
Q1 2026$13.9B$14.2B9.613.6
Q2 2026$10.3B$10.6B7.110.0
Refreshed 1h ago
Charts: revenue, profit, cash flow & valuation
CashDebt
Gross marginOperating marginNet margin
P/EP/S
CashDebt
Gross marginOperating marginNet margin
P/EP/S
Next catalyst
Catalysts
Next catalyst
Catalysts
Earnings
2027-04-01
Revenue est. $2.5B · Updated 1h ago
Dividend
$0.07
2026-09-01
No unusual perp activity right now.
FMP reference data
Market context
FMP reference data
Market context
Hong Kong Stock Exchange
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6DateEPS estimateRevenue estimateGrowthAnalysts
FY 20260.25$5.4B+14%16
FY 20270.26$5.8B+22%16
FY 20280.29$6.3B+33%15
FY 20290.25$6.8B+44%9
FY 20300.26$7.5B+59%6
Q2 20270.06$2.1B+46%1
Company events
62027-04-01EarningsActual - / Estimate 0.11-
2026-09-01Dividend$0.07-
2026-08-19EarningsActual 0.22 / Estimate 0.14Beat
2026-06-24Dividend$0.05-
2026-03-26EarningsActual 0.01 / Estimate 0.07Miss
2025-08-29Dividend$0.05-
Peer comparison
Similar listed perpsRevenue mix
PendingSegment data is not available yet.
Analysts
PendingNo analyst data available yet.
Ownership
SINOBIOPHARM-PERPOwnership data is being populated.
Filings
PendingNo filings available yet.
Transcripts
PendingNo transcripts available yet.
Company news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.No articles from Reuters, WSJ, Bloomberg or FT for this company in our feed.
Analyst track record
How the analysts covering SINOBIOPHARM have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 0 | 0 |
| Analysts | 0 | 0 |
| Buy / hold / sell | – | – |
| Upgrades / downgrades / initiations | 0 / 0 / 0 | 0 / 0 / 0 |
| Price targets hit / missed | – | – |
| Avg. return after a rating (TipRanks) | – | – |
| Best / worst call | – / – | – / – |
After buy calls on this stock: not enough measured cases yet
TipRanks data via FMP · computed Sep 24, 2026 · 0 ratings
Frequently asked questions
Where can I trade SINOBIOPHARM perpetual futures?
Sino Biopharmaceutical Limited (SINOBIOPHARM) perpetual futures trade on 1 crypto venues, including Gate.io. PerpEquities compares them by live price, funding rate, open interest and liquidity.
Can I trade SINOBIOPHARM around the clock?
Yes. Unlike the underlying stock, SINOBIOPHARM perpetuals trade 24/7 — including weekends and outside regular market hours.
What is the funding rate on SINOBIOPHARM perpetuals?
Right now the SINOBIOPHARM perp funding rate is 0.0% annualized (venue median), ranging from 0.0% to 0.0% across 1 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.
How does the SINOBIOPHARM perp price compare to the Sino Biopharmaceutical Limited stock?
The venue-median SINOBIOPHARM perp mark is $0.72 versus a reference stock price of $0.72, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.
What is a SINOBIOPHARM perpetual future?
A SINOBIOPHARM perpetual is a derivative that tracks the price of Sino Biopharmaceutical Limited with no expiry date. It lets you take long or short exposure to Sino Biopharmaceutical Limited on crypto venues, around the clock.
What is SINOBIOPHARMUSDT perpetual?
SINOBIOPHARMUSDT is the symbol most crypto exchanges use for the Sino Biopharmaceutical Limited perpetual settled in USDT (Tether). It tracks the SINOBIOPHARM share price through an index, trades 24/7 with leverage and never expires.
Embed this asset
<a href="https://perpequities.com/stocks/sinobiopharm-perp"><img src="https://perpequities.com/badge/sinobiopharm-perp.svg" width="240" height="64" alt="SINOBIOPHARM perpetuals · perpequities.com" loading="lazy"></a>